CRISPR Intelligence: Advanced Therapeutic R&D Platform

An advanced R&D platform for designing, predicting, and validating CRISPR-based therapeutics with unparalleled precision and speed.

CRISPR Intelligence: Advanced Therapeutic R&D Platform

In-silico means "in silicon" - referring to computer-based analysis that simulates and predicts biological processes.

An advanced R&D platform for designing, predicting, and validating CRISPR-based therapeutics with unparalleled precision and speed.

Research Use Only (RUO) - All outputs are for research purposes and not for diagnostic use

Core Capabilities

3 advanced AI-powered capabilities designed to transform your workflow

Predict: CRISPR Target Validation

Capability Deep Dive

Technical Approach

ClinVar validation for variant impact prediction. Analyzes target sites for functional variants that could affect gRNA binding efficiency.

Research Use Only • Validated Performance

The Value Proposition Flywheel

Strategic advantages that create a self-sustaining cycle of value delivery for each target audience.

For Scientists & Research Labs

  • Design with Unprecedented Confidence: Leverage best-in-class AI to design highly potent and specific guide RNAs from the start, dramatically increasing the success rate of your editing experiments and minimizing costly validation cycles.
  • Go from Raw Data to Actionable Insight, Faster: Let our AI Co-Pilot handle the heavy lifting of complex NGS data analysis and therapeutic contextualization, transforming your experimental results into clear, decision-ready insights in a fraction of the time.
  • Democratize Advanced Computational Biology: Access a suite of sophisticated AI tools for variant effect prediction, off-target analysis, and experimental design, without needing a dedicated bioinformatics team. Focus on your science, not on building analysis pipelines.
  • Produce High-Impact, Publishable Results: Generate higher quality, more reproducible data with AI-guided experimental design and analysis, strengthening your publications, grant applications, and contributions to the field.

For Biotechnology & Pharmaceutical Leaders

  • De-Risk Your Therapeutic Pipeline: Make more informed go/no-go decisions with AI-driven insights into target validity, off-target safety, and potential translational hurdles, significantly reducing the risk profile of your preclinical programs.
  • Accelerate Timelines to the Clinic: Shorten the entire discovery and preclinical development cycle for CRISPR therapies by streamlining design, automating complex analysis, and contextualizing results for therapeutic viability from day one.
  • Build a Moat Around Your IP: Strengthen your intellectual property position with novel, highly optimized, and well-characterized gene editing strategies and therapeutic candidates designed and validated through the platform.
  • Maximize Your R&D Investment: Improve the overall efficiency and success rate of your therapeutic programs, ensuring your resources are focused on the most promising candidates and strategies, leading to a higher potential return on investment.

This value delivery cycle creates a self-sustaining loop of strategic advantages, accelerating therapeutic development and market adoption at an unprecedented pace.

Our platform operationalizes these capabilities into a structured, seven-step in-silico workflow that delivers real business value:

From data curation to final validation, our automated pipeline transforms complex biological challenges into engineered therapeutic solutions.

  • 1. Problem Framing & Data Curation

    Assemble genomic loci, clinical variants, and DMS datasets to define the therapeutic target space.

  • 2. Target Assessment (Discriminative)

    CrisPRO zero-shot ΔLL scoring in 8,192 bp context to evaluate on-target activity.

  • 3. Mechanistic Triage & Hypothesis

    CrisPRO embeddings for exon/intron classification to understand the biological impact.

  • 4. Design (Generative)

    CrisPRO proposals with Enformer+Borzoi scoring to generate high-efficacy gRNA candidates.

  • 5. In-Silico Validation

    Aggregate scores with structure metrics (pLDDT/PAE) to validate designs computationally.

  • 6. Feedback & Calibration

    Lightweight supervised heads on CrisPRO embeddings to continuously refine and calibrate models.

  • 7. Reporting & Provenance

    Evidence reports with traceable citations and complete data provenance for regulatory and research needs.

Strategic Conclusion

The CRISPR Intelligence Platform transforms therapeutic design from a manual, iterative process into a scalable, AI-driven system. We provide the tools to advance the fight against genetic disease through precision medicine.

Explore Other Co-Pilots

Chemo Co‑Pilot: In‑Silico Chemotherapy Guidance

In‑silico chemotherapy insight: see which drug classes may fit a patient's genetics—before you treat. Clear signals, confidence, and sources (research‑mode).

Clinical Trials Co‑Pilot: In‑Silico Trial Matching

Find matching trials in minutes. Clear eligibility and a shareable one‑pager (research‑mode).

Pathway View: What's Driving This?

A simple biology story for each case: which pathways look most involved, and how that ties to therapy (research‑mode).

Therapy Fit: In‑Silico Drug Ranking

See which drug classes may fit a patient's genetics—before treatment. Clear ranking, confidence, and sources (research‑mode).

Toxicity Risk (Germline): In‑Silico Side‑Effect Hints

See simple, genetics‑aware side‑effect hints to plan conservatively—before treatment (research‑mode).